LPCN Lipocine Inc.
Healthcare$2.26+0.00%ClosedMarket Cap: $13.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.67
P/S
6.55
EV/EBITDA
-0.67
DCF Value
$0.75
FCF Yield
-76.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-8.2%
Operating Margin
-605.9%
Net Margin
-571.1%
ROE
-66.7%
ROA
-45.1%
ROIC
-53.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $119.4K | 87.6% | $-3.8M | $-3.7M | $— | — |
| Q4 null | $1.1M | 98.7% | $-2.5M | $-2.4M | $— | — |
| FY null | $2.0M | -334.3% | $-10.4M | $-9.6M | $— | — |
| Q3 null | $114.6K | 100.0% | $-3.4M | $-3.2M | $— | — |
| Q2 null | $622.8K | -243.1% | $-2.4M | $-2.2M | $— | — |
| Q1 null | $93.9K | 100.0% | $-2.1M | $-1.9M | $— | — |
| Q4 null | $3.5M | 100.0% | $1.5M | $1.8M | $— | — |
| FY null | $11.2M | 100.0% | $-1.2M | $8.4K | $— | — |
| Q3 null | $0.00 | NaN% | $-2.6M | $-2.2M | $— | — |
| Q2 null | $89.6K | -1993.1% | $-3.3M | $-3.1M | $— | — |
| Q1 null | $7.6M | 100.0% | $3.2M | $3.5M | $— | — |
| Q4 2023 | $216.2K | 100.0% | $-2.6M | $-2.3M | $-0.43 | — |